RDX-002 Investigated for Post-Meal Triglycerides After Stopping GLP-1 Agonists

Obesity is a global health challenge often managed with GLP-1 agonists (glucagon-like peptide-1 receptor agonists, a class of drugs mimicking a natural hormone to regulate blood sugar and appetite) like semaglutide and tirzepatide, which are highly effective for weight loss. However, discontinuing these medications can lead to weight regain and potential metabolic disturbances, including elevated triglycerides (fats in the blood) after meals. This study aims to determine if RDX-002 can mitigate postprandial triglyceride elevation in patients who have recently stopped GLP-1 agonist therapy.

This randomized, double-blind, placebo-controlled trial has concluded its data collection, and its primary objective was to determine if RDX-002 could significantly lower postprandial triglycerides (fat levels in the blood after eating) in adults who recently stopped semaglutide or tirzepatide for obesity. Researchers aimed to observe a measurable reduction in these fat levels after a high-fat meal in the RDX-002 group compared to placebo. > The most critical finding, once reported, will be whether RDX-002 demonstrates a statistically significant decrease in postprandial triglyceride levels, indicating its potential to manage metabolic health post-GLP-1 agonist therapy. Secondary aims included assessing the impact of RDX-002 on body weight trajectory (how weight changes over time) and fasting cholesterol levels over the 12-week treatment duration. The full results are anticipated to provide quantitative data on these metabolic markers, comparing the RDX-002 treatment group against the placebo control.